Search results for "Nous"

showing 10 items of 2193 documents

Significance of hyperlactatemia in acute hypnotic drug poisoning

1981

Lactate concentration, fibrinogen and fibrin(ogen) -- degradation-products in central venous blood were analysed in 35 unconscious patient with acute hypnotic drug poisoning (HDP) and compared with the results in 13 healthy control persons undergoing the same degree of forced diuresis via central venous catheters. Blood samples were taken on admission and at 12 h intervals up to 36 h after admission. Patients with HDP were attributed to the categories of moderate intoxications (n = 17) and severe intoxications (n = 18) according to their clinical condition. On admission, blood lactate was significantly higher in severe intoxication (3.90 +/- 2.94 mmol/l) as compared to the control group (1.…

AdultMaleUnconsciousnessFibrinogenFibrinFibrin Fibrinogen Degradation ProductsDrug DiscoverymedicineBlood lactateHumansHypnotics and SedativesIn patientGenetics (clinical)biologybusiness.industryUnconsciousnessHemodynamicsFibrinogenGeneral MedicineVenous bloodHypnotic drugAnesthesiaLactatesbiology.proteinMolecular MedicineFemaleHyperlactatemiamedicine.symptombusinessmedicine.drugKlinische Wochenschrift
researchProduct

Continuous therapy with transdermal nitroglycerin does not affect biomarkers of vascular inflammation and injury in healthy volunteers.

2009

Continuous exposure to nitroglycerin (GTN) results in development of tolerance and is associated with increased free radical production and abnormal endothelial function. Elevated plasma biomarkers of inflammation have been shown to be associated with endothelial dysfunction in most cardiovascular conditions. It remains unclear whether exposure to GTN is also associated with increased biomarkers of endothelial and vascular injury or vascular inflammation. In an investigator-blind study, a total of 28 healthy volunteers were randomized to continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days) or no therapy. Venous blood was collected on day 0 and day 7. Plasma levels of markers such as …

AdultMaleVasculitisTime FactorsEndotheliumAdolescentPhysiologyVasodilator AgentsInflammationPharmacologyAdministration CutaneousArginineLesionNitroglycerinYoung AdultPhysiology (medical)MedicineHumansEndothelial dysfunctionTransdermalPharmacologyDose-Response Relationship Drugbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaGeneral MedicineVenous bloodmedicine.diseaseLipoproteins LDLDose–response relationshipP-Selectinmedicine.anatomical_structureAnesthesiacardiovascular systemTumor necrosis factor alphaEndothelium Vascularmedicine.symptombusinessCell Adhesion MoleculesBiomarkerscirculatory and respiratory physiologyCanadian journal of physiology and pharmacology
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis

2004

OBJECTIVE: To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behçet's disease (BD). METHODS: Included were 118 consecutive Italian BD patients followed over a 3-year period (1997-1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. RESULTS: Vascular lesions were observed in …

AdultMaleVenous ThrombosisFactor V Leiden mutation Prothrombin G20210A mutationAdolescentGenotypeBehcet SyndromeFactor VMiddle AgedBehc ̧et’s disease; Deep vein thrombosis; Factor V Leiden mutation Prothrombin G20210A mutationAdolescent; Adult; Behcet Syndrome; Factor V; Female; Gene Frequency; Genotype; Humans; Italy; Male; Middle Aged; Prothrombin; Risk Factors; Venous Thrombosis; Point MutationGene FrequencyItalyDeep vein thrombosiRisk FactorsFactor V Leiden mutationHumansPoint MutationFemaleProthrombinProthrombin G20210A mutationBehcet’s disease
researchProduct

Deep venous thrombosis: Behaviour of the polymorphonuclear leukocyte integrin pattern at baseline and after in vitro activation

2005

In a group of 18 subjects with acute deep venous thrombosis (DVT), evidenced by clinical examination and echo-color-Doppler, we examined the phenotypical expression of the polymorphonuclear leukocyte (PMN) beta2-integrins (CD11a, CD11b, CD11c, CD18), obtained by using a flow cytofluorimeter. The evaluation was performed before and after in vitro activation (prolonged for 5 and 15 minutes) with 4-phorbol 12-myristate 13-acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (fMLP). In DVT subjects, at baseline, the phenotypical expression of CD11b was decreased and that of CD11c was increased when compared with normal controls; no difference was found in CD11a and CD18 expression. In norm…

AdultMaleVenous ThrombosisIntegrinsSettore MED/09 - Medicina InternaCD11 AntigensNeutrophilsDeep venous thrombosis; polymorphonuclear leukocyte integrins; polymorphonuclear leukocyte activationMiddle AgedFlow CytometryNeutrophil ActivationDeep venous thrombosis polymorphonuclear leukocyte integrins polymorphonuclear leukocyte activationpolymorphonuclear leukocyte integrinsGene Expression RegulationCD18 AntigensCase-Control StudiesDeep venous thrombosisHumansTetradecanoylphorbol AcetateFemalepolymorphonuclear leukocyte activationAged
researchProduct

Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease

1988

In a six-month multicenter feasibility and safety study, 20 patients, who all had a congenital deficiency of alpha-1-protease inhibitor (A1PI) of the PiZ phenotype accompanied by a chronic obstructive lung disease, were treated with human-plasma-derived A1PI. A weekly dose of 60 mg/kg, administered intravenously, was shown to be sufficient to maintain patient serum levels above the threshold limit of 35 percent, the serum level of healthy persons of the MZ phenotype. This is supposed to be the minimal effective level for protection against the elastolytic attack of the lung and, therefore, satisfies one of the most important criteria of feasibility of long-term replacement therapy. The glob…

AdultMalealpha 1-Antitrypsin DeficiencymedicineHumansLung Diseases ObstructiveInfusions IntravenousAgedRadial immunodiffusionClinical Trials as TopicLungPancreatic Elastasebiologybusiness.industryBlood ProteinsGeneral MedicineMiddle AgedOuchterlony double immunodiffusionTrypsinmedicine.diseaseAlpha-1 Protease Inhibitor DeficiencyObstructive lung diseasePhenotypemedicine.anatomical_structureImmunologybiology.proteinFemaleAntibodyLung Volume MeasurementsbusinessNephelometrymedicine.drugThe American Journal of Medicine
researchProduct

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

2007

The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30 min after the treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at T1 and T2, respectively. In episodes treated with OTFC, pain int…

AdultMalecancer painCancer Researchintravenous morphineAdolescentTransmucosal fentanyl; intravenous morphine; episodic-breakthrough pain.Transmucosal fentanylAdministration OralPainFentanylNeoplasmsClinical StudiesmedicineHumansDosingChildOTFCAdverse effectCross-Over StudiesMorphinebusiness.industryInfantopioidsMiddle Agedbreakthrough painCrossover studyAnalgesics OpioidFentanylRegimenepisodic-breakthrough pain.OncologyOpioidChild PreschoolAnesthesiaInjections IntravenousMorphineFemalebusinessCancer painmedicine.drugBritish Journal of Cancer
researchProduct

Immunophenotypical comparison of Gaucher's and pseudo-Gaucher cells.

1996

An immunohistochemical study on bone marrow biopsies and spleens of patients with Gaucher's disease and chronic myeloid leukemia was performed to investigate the immunophenotype of Gaucher's cells and pseudo-Gaucher cells. A panel of antibodies was used which were reactive on paraffin-embedded tissues and directed against different hematopoietic lineage cells. Gaucher's cells and pseudo-Gaucher cells expressed a very similar immunophenotype and displayed an intense reaction for the monocytic antibodies tested, thus confirming their common origin and that they belong to the same system. The expression of HLA-DR antigens was much stronger in Gaucher's than in pseudo-Gaucher cells. This last f…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyBone Marrow CellsBiologyPathology and Forensic MedicineImmunophenotypingNuclear FamilyImmunoenzyme TechniquesImmunophenotypingImmune systemAntigenAntigens CDLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansAgedPhagocytesGaucher Diseasenutritional and metabolic diseasesMyeloid leukemiaGeneral MedicineHLA-DR AntigensMiddle Agedmedicine.diseasenervous system diseasesLeukemiamedicine.anatomical_structureImmunologybiology.proteinImmunohistochemistryFemaleBone marrowAntibodySpleenPathology international
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in …

2009

Plasma levels of prolactin (PRL) and the butyrophenone neuroleptic benperidol (BPD) were closely followed 0 to 48 h after acute application of 6 mg BPD as intravenous injection, orally as liquid, and orally as tablets in 12 schizophrenic patients using a partially randomized cross over design. Drug concentrations showed application specific pharmacokinetic behavior with complete elimination within 48 h. All three applications led to a biphasic PRL response with pronounced initial plasma PRL peaks returning to baseline levels within 48 h. The results suggest that after acute neuroleptic challenge BPD plasma levels as low as 2-3 ng/ml can be sufficient for complete depletion of pituitary PRL …

AdultMaleendocrine systemmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAdministration OralPharmacologyBenperidolchemistry.chemical_compoundEndocrinologyPharmacokineticsOral administrationInternal medicinemental disordersInternal MedicinemedicineHumansCross-Over Studiesbusiness.industryBenperidolHomovanillic acidDopaminergicAntagonistHomovanillic AcidGeneral MedicineProlactinProlactinEndocrinologychemistryInjections IntravenousSchizophreniaFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHormoneExperimental and Clinical Endocrinology & Diabetes
researchProduct

Regional distribution of opioidergic nerves in human and canine prostates

1989

The regional distribution of opioidergic nerves in the juvenile and adult human prostate and in the adult canine prostate has been studied immunohistochemically using well-characterized polyclonal antisera against multiple opioid peptides. Nerves displaying immunoreactivity (ir) for the proenkephalin (PRO-ENK) derivatives met-enkephalin (ME), leuenkephalin (LE), octapeptide, and heptapeptide (ordered in decreasing frequency) were present in the dorsolateral stroma of human prostate. In canine prostate, the situation was similar, but the number of opioid-ir nerve fibers was lower than in human prostate. In both species, staining for the prodynorphin (PRO-DYN) derivatives dynorphin A and alph…

AdultMaleendocrine systemmedicine.medical_specialtyStromal cellAdolescentEnkephalin MethionineUrologyDynorphinBiologyEjaculatory ductchemistry.chemical_compoundDogsProstateInternal medicinemedicineAnimalsHumansOpioid peptideAgedEndogenous opioidProstateInfantDynorphin AMiddle AgedImmunohistochemistryPeptide FragmentsProenkephalinEndocrinologymedicine.anatomical_structureOncologychemistryChild PreschoolEnkephalin LeucineThe Prostate
researchProduct